Hereditary breast-ovarian cancer at the bedside: Role of the medical oncologist

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 740-753

  Lynch, Henry T ^a   Snyder, Carrie L ^a   Lynch, Jane F ^a   Riley, Bronson D ^a   Rubinstein, Wendy S ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ANXIETY; BREAST CANCER; CANCER DIAGNOSIS; COMPLIANCE (PHYSICAL); DNA DETERMINATION; EMPLOYMENT DISCRIMINATION; FAMILIAL CANCER; FAMILY HISTORY; FEAR; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MUTATIONAL ANALYSIS; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ADULT; BREAST TUMOR; COUNSELING; FEMALE; GENETICS; MALE; MUTATION; ONCOLOGY; OVARY TUMOR; PEDIGREE; PHYSICIAN ATTITUDE; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COUNSELING; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MALE; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PEDIGREE; PHYSICIAN'S ROLE; RISK FACTORS;

EID: 0037441808     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.096     Document Type: Review

References (87)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. de Jong MM, Nolte IM, te Meerman GJ, et al: Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39:225-242, 2002
3. Lynch HT, Lynch J, Conway T, et al: Hereditary breast cancer and family cancer syndromes. World J Surg 18:21-31, 1994
4. Lynch HT, Krush AJ, Lemon HM, et al: Tumor variation in families with breast cancer. J Am Med Assoc 222:1631-1635, 1972
5. Lynch HT, Krush AJ: Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 133:644-648, 1971
6. Lynch HT, Fusaro RM (eds): Cancer-Associated Genodermatoses. New York, Van Nostrand Reinhold Co, 1982
7. Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer. New York, McGraw-Hill, 1998
8. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al: Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 and BRCA2 mutations. Nat Genet 31:55-59, 2002
9. Biggs PJ, Bradley A: A step toward genotype-based therapeutic regimens for breast cancer in patients with BRCA2 mutations? J Natl Cancer Inst 90:951-953, 1998
10. Graeber TG, Eisenberg D: Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles. Nat Genet 29:295-300, 2001
11. Fraser CM, Dando MR: Genomics and future biological weapons: The need for preventive action by the biomedical community. Nat Genet 29:253-256, 2001
12. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
13. Petricoin EF, III, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002
14. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
15. Risch HA, McLaughlin JR, Cole DEC, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001
16. Sweet KM, Bradley TL, Westman JA: Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol 20:528-537, 2002
17. David KL, Steiner-Grossman P: The potential use of tumor registry data in the recognition and prevention of hereditary and familial cancer. N Y State J Med 91:150-152, 1991
18. Lynch HT: Cancer and the family history trail. N Y State J Med 91:145-147, 1991 (editorial)
19. Lynch HT, Mulcahy GM, Harris RE, et al: Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 41:2055-2064, 1978
20. Pegalis SE, Wchsmann HF: Negligence and cancer. Trial 22:48-52, 1986
21. Hernandez v United States, 636 F2d 704 (DC Cir 1980)
22. Hicks v United States, 368 Fed2 626 (4th Cir 1966)
23. O'Brien v Stover, 443 F2 1013 (8th Cir 1971)
24. Severin MJ: Heredity cancer litigation: A status report. Oncology 10:211-214, 1996
25. Severin MJ: Genetic susceptibility for specific cancers: Medical liability of the clinician Cancer 86:2564-2569, 1999
26. Severin MJ: Breast carcinoma litigation: Medical questions, legal answers. Cancer 80:600-605, 1997 (suppl)
27. Bennett RL, Steinhaus KA, Uhrich SB, et al: Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet 56:745-752, 1995
28. Lynch HT: Family Information Service and hereditary cancer. Cancer 91:625-628, 2001
29. Lynch HT, Lemon SJ, Marcus JN, et al: Breast cancer genetics: heterogeneity, molecular genetics, syndrome diagnosis, and genetic counseling, in Bland KI, Copeland EMI (eds): The Breast: Comprehensive Management of Benign and Malignant Diseases, vol. 1, ed 2. Philadelphia, PA, W. B. Saunders, 1998, pp 370-394
30. Lynch HT, Lemon SJ, Durham C, et al: A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79:2219-2228, 1997
31. Kauff ND, Scheuer L, Robson ME, et al: Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 3:422-425, 2001
32. Peterson EA, Milliron KJ, Lewis KE, et al: Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11:79-87, 2002
33. Peters JA, McAllister CL, Rubinstein WS: Qualitative cancer genetic counseling research, part I: Ethnography in a cancer clinic. J Genet Couns 10:133-150, 2001
34. Peters JA, McAllister CL, Rubinstein WS: Qualitative cancer genetic counseling research, part II: Findings from an exploratory ethnograhic study in a cancer clinic. J Genet Couns 10:151-168, 2001
35. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001
36. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999
37. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
38. Narod SA, Brunet J-S, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356:1876-1881, 2000
39. Lynch HT, Lynch JF, Rubinstein WS: Prophylactic mastectomy: Obstacles and benefits. J Natl Cancer Inst 93:1586-1587, 2001
40. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002
41. Eisen A, Rebbeck TR, Wood WC, et al: Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18:1980-1995, 2000
42. Dyck HG, Hamilton TC, Godwin AK, et al: Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer (Pred Oncol) 69:429-436, 1996
43. Hensley ML, Castiel M, Robson ME: Screening for ovarian cancer: What we know, what we need to know. Oncology 14:1601-1607, 2001
44. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: Screening, treatment, and follow-up. Gynecol Oncol 55:S4-S14, 1994
45. Droegemueller W: Screening for ovarian cancer: Hopeful and wishful thinking. Am J Obstet Gynecol 170:1095-1098, 1994
46. Hallowell N, Jacobs I, Richards M, et al: Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy. J Med Genet 38:683-691, 2001
47. Meijers-Heijboer H, van Geel B, van Putten WLJ, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001
48. Meiser B, Butow P, Barratt A, et al: Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75:122-129, 1999
49. Lerman C, Hughes C, Croyle RT, et al: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75-80, 2000
50. Berry DA, Iversen ES, Jr., Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2 and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002
51. Liede A, Metcalfe K, Offit K, et al: A family with three germline mutations in BRCA1 and BRCA2. Clin Genet 54:215-218, 1998
52. Lynch HT, McComb RD, Osborn NK, et al: Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. Cancer 88:433-439, 2000
53. Harkin DP: Uncovering functionally relevant signaling pathways using microarray-based expression profiling. Oncologist 5:501-507, 2000
54. Venkitaraman AR: Breast cancer genes and DNA repair. Science 286:1100-1102, 1999
55. Scully R, Chen J, Plug A, et al: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88:265-275, 1997
56. Levy-Lahad E, Lahad A, Eisenberg S, et al: A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98:3232-3236, 2001
57. Swift M, Morrell D, Massey RB, et al: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1831-1836, 1991
58. Broeks A, Urbanus JH, Floore AN, et al: ATM-heterozygous germline mutations contribute to breast cancer susceptibility. Hum Genet 66:494-500, 2000
59. Sharan SK, Morimatsu M, Albrecht U, et al: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810, 1997
60. Connor F, Bertwistle D, Mee PJ, et al: Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 17:423-430, 1997
61. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978-985, 1998
62. Coleman CN: Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. Acta Oncol 38:55-59, 1999 (suppl)
63. Friedenson B: Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer. Medscape Portals, Inc., Medscape General Medicine 2, 2000 http://www.medscape.com/viewarticle/408048. Accesses January 6, 2003
64. Pierce LJ, Strawderman M, Narod SA, et al: Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360-3369, 2000
65. Turner B, Harrold E, Matloff E, et al: BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017-3024, 1999
66. Marcus JN, Page DL, Watson P, et al: BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer 80:543-556, 1997 (suppl)
67. Marcus JN, Watson P, Page DL, et al: BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44:275-277, 1997
68. Marcus JN, Watson P, Page DL, et al: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996
69. Lakhani SR, van de Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002
70. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
71. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
72. Gruvberger S, Ringner M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001
73. Martin KJ, Graner E, Li Y, et al: High sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci USA 98:2646-2651, 2001
74. Kudoh K, Ramanna M, Ravatn R, et al: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60:4161-4166, 2000
75. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
76. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
77. Perou CM, Jeffrey SS, van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96:9212-9217, 1999
78. Martin KJ, Kritzman BM, Price LM, et al: Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res 60:2232-2238, 2000
79. Zajchowski DA, Bartholdi MF, Gong Y, et al: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61:5168-5178, 2001
80. West M, Blanchette C, Dressman H, et al: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462-11467, 2001
81. Hedenfalk I, Duggan D, Chen Y, et al: Gene expression profiles in hereditary breast cancer. N Engl J Med 344:539-548, 2001
82. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
83. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
84. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
85. Ramsey SD, Clarke L, Etzioni R, et al: Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 135:577-588, 2001
86. Grann VR, Panageas KS, Whang W, et al: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979-985, 1998
87. Schrag D, Kuntz KM, Garber JE, et al: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283:617-624, 2000